MEDPRO SYSTEMS
LIVE

Serial Number

98048406

Owner

MedPro Systems LLC

Attorney

Christine Amara

First Use Date

Apr 1, 2021

Filing Date

Jun 19, 2023

Add to watchlist:

No watchlists yet
View on USPTO

MEDPRO SYSTEMS Trademark

Serial Number: 98048406 • Registration: 7432933

MEDPRO SYSTEMS is a trademark filed by MedPro Systems LLC on June 19, 2023. The trademark is classified under Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

MedPro Systems LLC (43 trademarks)

100 VALLEY ROAD, Suite 201
Mt. Arlington, NJ 07856

Entity Type: 10

Trademark Details

Filing Date

June 19, 2023

Registration Date

July 2, 2024

First Use Anywhere

April 1, 2021

First Use in Commerce

April 1, 2021

Published for Opposition

April 16, 2024

Goods & Services

Consulting services in the nature of conducting trainings for life sciences, pharmaceuticals, biotechnology, and medical device companies personnel and partners on pharmaceutical and medical device compliance program requirements, fraud and corruption laws and regulations, industry codes and best practices; consulting services, namely, developing and providing trainings for life sciences, pharmaceutical, biotechnology, and medical device companies in the field of corporate compliance and transparency programs

Business consulting services for life sciences, pharmaceuticals, biotechnology and medical device companies in the nature of regulatory compliance program development and enhancement and transparency program support, namely, reviewing program status and performing gap analyses, drafting programs plans, program implementation support, development and improvement of policies, standard operating procedures and codes of conduct; business consulting services in the nature of monitoring of pharmaceutical and medical device manufacturer interactions with healthcare professionals, healthcare organizations, patients, and other customers; business consulting services in the nature of auditing of pharmaceutical and medical device manufacturer interactions with and payments to healthcare professionals, healthcare organizations, patients, and other customers; business consulting services in the nature of business investigation support for internally and externally raised complaints made against a pharmaceutical or medical device manufacturer related to potential violations of their company policy or code, industry code, or law or regulation; transparency reporting regulatory submission management, namely, assisting others in preparing and filing regulatory submissions in the field of transparency reporting for pharmaceutical, biotechnology and medical device companies; business consulting services, namely, tracking and monitoring regulatory requirements for others in the field of life sciences, pharmaceuticals, biotechnology, and medical devices for regulatory compliance; business consulting services, namely, compliance program gap analysis for life sciences, pharmaceutical, biotechnology, and medical device companies

Regulatory compliance consulting in the field of life sciences, pharmaceuticals, biotechnology, and medical devices; consulting services to assist life sciences, pharmaceutical, biotechnology and medical device companies in the fields of regulatory compliance, namely, compliance in the areas of aggregate spend disclosure reporting, the Prescription Drug Marketing Act, the Drug Supply Chain Security Act, Condition of Participation for Outpatient Services, Stark Law and Ohio Terminal Distributor of Dangerous Drugs requirements; regulatory compliance audits for life sciences, pharmaceutical, biotechnology and medical device companies to assist with regulatory compliance; consulting services in the field of life sciences, pharmaceutical, biotechnology and medical device corporate compliance program and transparency program development, implementation and support; providing online searchable databases and information concerning historical, current and pending laws, regulations, and guidance documents governing the life sciences industry; regulatory compliance consulting services in the field of aggregate spend disclosure reporting; regulatory and compliance information for pharmaceutical, biotechnology and medical device companies, and for entities involved in the drug and device supply chain, regarding transparency and aggregate spend, marketing, and additional compliance requirements; regulatory compliance consulting, namely, reviewing, developing, training on and assisting with the implementation and monitoring of standards, practices, procedures and policies to support regulatory compliance for companies in the fields of life sciences, pharmaceuticals, biotechnology, and medical devices

Software as a service (SaaS) services featuring software for use to assist in tracking and reporting healthcare practitioner and healthcare organization interactions and complying with international, federal, state and local spend and transparency laws and regulations; software as a service (SaaS) services featuring software to assist pharmaceutical, biotechnology and medical device companies in managing, validating and enriching healthcare organization and healthcare practitioner data attributes in connection with regulatory compliance, sales and marketing efforts

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 2, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 2, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 16, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 16, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 27, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 11, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 5, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 5, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 1, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 1, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 1, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 26, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jul 22, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 21, 2023 NWOS
NEW APPLICATION ENTERED
Jun 22, 2023 NWAP